The Pharmaceutical Industry And Health Professional Services. Sirtris Pharmaceuticals Inc Sirtris Pharmaceuticals, Inc. operates as a biopharmaceutical company. Private Company Reports provide up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.S… Multistage venture capital investors with focus Technology, Healthcare and Consumer : United States : 6630 Fund management: edit [4], Sirtris went public in 2007 and was subsequently purchased and made a subsidiary of GlaxoSmithKline in 2008 for $720 million. Sirtris Pharmaceuticals Products Add Product. Sirtris Pharmaceuticals From Wikipedia, the free encyclopedia Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Thomas Salzmann is Former Chairman at Satori Pharmaceuticals Inc. See Thomas Salzmann's compensation, career history, education, & memberships. Really? London-based Glaxo said Tuesday it agreed to buy Sirtris in an all-cash tender offer at $22.50 a share. Sirtris Pharmaceuticals Inc., a biopharmaceutical company engaged in developing small molecule drugs that target the sirtuins, a recently discovered family of seven enzymes associated with the aging process, was acquired by GlaxoSmithKline (NYSE: GSK) in June of 2008 and now operates as the company’s wholly-owned subsidiary. Sirtris Pharmaceuticals Inc. has been sold for $720 million to international pharmaceutical company GlaxoSmithKline (NYSE: GSK), just four years after the biotechnology startup launched. Their focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). See Appendix for pictures of the covers of the Wall Street Journal and Fortune. Acquired by GSK (GlaxoSmithKline) on April 22, 2008 Founded: January 01, 2004 Whether any of those compounds are going to be tested on Parkinson’s disease is yet to be determined. Should the company establish a proposed alliance with a pharmaceutical firm? The research is at a very early stage and it may take years before the drug could be submitted for approval. GlaxoSmithKline plc (NYSE: GSK) announced today the successful completion of the tender offer by its wholly-owned subsidiary Fountain Acquisition Corporation (FAC) for shares of common [1][3] The company's initial product was called SRT501, and was a formulation of reservatrol. Advantages of Living in America. Dear David: Thank you for agreeing to become a consultant to Sirtris Pharmaceuticals, Inc. (the "Company"). Sirtris Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. By continuing to ... Use your energy where it's needed most — ensuring that your products are in compliance and … Their stock opened with $10.00 in its May 23, 2007 IPO. But Sirtris pulled it off, via M&A, when GSK tendered a whopping $720 million for it in April. Sirtris Pharmaceuticals Team Add Team Member. Founded in 2004, Sirtris went public in May 2007 and continues as an independent discovery performance unit within GSK. [15][16], In 2013 GSK shut down Sirtris and its development candidates were absorbed into GSK, where research and development continued. Consultant to the CEO Jan 2004 to Jan 2006 Kevin Bitterman. Just what did GlaxoSmithKline (GSK) get for its dime when, in 2008, it dropped $720 million (or 72 billion dimes) to buy Sirtris Pharmaceuticals? "Sirtris Pharmaceuticals Living Healthier Longer" Essays and Research Papers . Global Market Direct's pharmaceuticals report, "Sirtris Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Sirtris Pharmaceuticals, Inc.'s research and development focus. A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Sirtris has already started a larger drug study. [15][16] The company said at that time that it was focused on two compounds called SRT2104 and SRT2379 that were not resveratrol analogs, had better drug-like qualities, and were more selective SIRT1 activators. In 2008, GlaxoSmithKline (GSK) purchased Sirtris Pharmaceuticals for $720 million in order to continue to expand its portfolio of potential drugs to be commercialized in the future. Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Active, Closed, Last funding round type (e.g. Sirtris Pharmaceuticals develops small molecule drugs for the treatment of aging and metabolic diseases. The successful organizations such as Sirtris Gsk's are the one who able to predict market trends better than others, provide resources to develop products and services to leverage those trends, able to counter competitors’ threats, and meet customers’ expected value proposition. The deal is another example of Pharma's interest in platform biotechs and its hunger for innovation. Health Centers; Information by Medical Specialty; Homepages; Health Websites; Buy Online Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. Sirtris Pharmaceuticals, Inc. was founded in 2008. Product Status Description; There are no products. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . Should the company establish a proposed alliance with a pharmaceutical firm? GlaxoSmithKline (GSK) is closing its Sirtris Pharmaceuticals office in Cambridge and fully integrating its research and development (R&D) operations with Philadelphia office. Sirtris Pharmaceuticals develops small molecule drugs for the treatment of aging and metabolic diseases. N9-808-112 MARCH 18, 2008 TOBY STUART DAVID KIRON Sirtris Pharmaceuticals: Living Healthier, Longer “You can live to be a hundred if you give up all the things that make you want to live to be a hundred. [15][16] GSK said it was terminating SRT501 due to side effects of nausea, vomiting, and diarrhea it caused, and because the compound's activity wasn't specific to SIRT1, at some doses it actually inhibited SIRT1, and the compound itself wasn't patentable. Professor Toby Stuart and Senior Researcher Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 1250 S COLLEGEVILLE RD COLLEGEVILLE, PA 19426 Get Directions (585) 275-5774. Business Info. As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. Toby Stuart, James Webber focus on Innovation & Entrepreneurship and Decision making, Entrepreneurship, Growth strategy, Leadership, Risk management. As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. And, should it in-license a second drug development candidate? [6], Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. Then in 2013, GlaxoSmithKline shut down Sirtris Pharmaceuticals completely, but indicated that they would be following up on many of Sirtris’s other sirtuins-activating compounds (Click here to read more on this). Pharmaceutical Preparations. [5] GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. See Appendix for pictures of the covers of the Wall Street Journal and Fortune. Solved Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged) case study solution include SWOT Analysis, PESTEL Analysis, VRIO Analysis, Porter Five Forces Analysis & Value Chain Analysis, BCG Growth Share Analysis. Get information, directions, products, services, phone numbers, and reviews on Sirtris Pharmaceuticals in Collegeville, undefined Discover more Pharmaceutical Preparations companies in Collegeville on … Sirtris Pharmaceuticals: Living Healthier, Longer Fortune, February 12, 2007. "[18][19], "Tests Begin on Drugs That May Slow Aging", "Former Sirtris Execs' Nonprofit Starts Selling Resveratrol with Potential Anti-Aging Effects Online", "UPDATED: GSK moves to shutter Sirtris' Cambridge office, integrate R&D", "The Sirtris Compounds: Worthless? CAMBRIDGE, Mass.- Sirtris Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today publication of a study by Sirtris and Harvard University scientists … Sirtris Pharmaceuticals, Inc. specializes in Pharmaceutical Preparations. Sirtris’ focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). the FDA require that animals of both sexes be included in non-clinical studies? Sirtris Pharmaceuticals: Living Healthier, Longer Fortune, February 12, 2007. The company's business plan was based on … For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Person Role Period; Brian Shin. Chemicals, Pharmaceuticals & Plastics. The firm is mulling to relocate some of the 60 staffers currently working at the site in Cambridge to Philadelphia office. Products; Resources; My Account; Talk to a D&B Advisor 1-800-280-0780. Business Directory. ", "SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1", "Doubt on Anti-Aging Molecule as Resveratrol Trial Is Halted", "GlaxoSmithKline Halts All Further Development Of Resveratrol Drug SRT501", "GSK absorbs controversial 'longevity' company : News blog", "GlaxoSmithKline Shuts Down Sirtris, Five Years After $720M Buyout", https://en.wikipedia.org/w/index.php?title=Sirtris_Pharmaceuticals&oldid=968238491, Biotechnology companies of the United States, Creative Commons Attribution-ShareAlike License, This page was last edited on 18 July 2020, at 03:23. Sirtris Pharmaceuticals acquired by GlaxoSmithKline, Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of current team members an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Medvedik has worked as a biotechnology consultant at Sirtris Pharmaceuticals and has taught molecular and synthetic biology to hundreds of students while at Harvard University, The Cooper Union, School of Visual Arts, Genspace and NYU. Pathway-oriented platforms are rare, and dealmaking around them can be complicated: partner too early or for too little and you risk giving away the store. Sirtris Pharmaceuticals, Inc. S. Sirtris Pharmaceuticals, Inc. Sirtris Pharmaceuticals Living Healthier Longer Case Study Solution & Analysis. And that was the case when GlaxoSmithKline, the British drug company with U.S. headquarters in the Triangle, announced its $720 million purchase of Massachusetts’ Sirtris Pharmaceuticals. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. PA. Collegeville. CAMBRIDGE, Mass.- Sirtris Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today publication of a study by Sirtris and Harvard University scientists in the journal Cell that reveals a new mechanism to slow aging. [1], The company was specifically focused on resveratrol formulations and derivatives as activators of the SIRT1 enzyme; Sinclair became known for making statements about resveratrol like: “(It's) as close to a miraculous molecule as you can find.... One hundred years from now, people will maybe be taking these molecules on a daily basis to prevent heart disease, stroke, and cancer.”[1] Most of the anti-aging field was more cautious, especially with regard to what else resveratrol might do in the body and its lack of bioavailability. Professor Toby Stuart and Senior Researcher GlaxoSmithKline (GSK) has offered to buy all outstanding shares of Sirtris Pharmaceuticals for $22.50 a share. See reviews, photos, directions, phone numbers and more for Sirtris Pharmaceuticals Inc locations in Cambridge, MA. Chemical base materials; Plastic products; Chemical products; Chemical industry plant and equipment; Rubber and plastic industry plant and equipment ; Health, medical and pharmaceutical; Rubber products; Construction. Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Many people from all over the world come to the United Stats to turn their Wheel of Fortune. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. Major HBR cases concerns on a whole industry, a whole organization or some part of organization; profitable or non-profitable organizations. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. [5][17][18] At that time, GSK/Sirtris' lead candidate was SRT2104, described as a "first-generation sirtuin-activating compound. [7][8][9][10][11][12], In August 2010, a nonprofit called the Healthy Lifespan Institute, which had been formed the year before by Westphal and Michelle Dipp, who joined GSK from Sirtris, began selling SRT501 as a dietary supplement online;[4] when this become public GSK required Westphal and Dipp, who were still GSK employees, to resign from the nonprofit. Sirtris Pharmaceuticals: Living Healthier, Longer by Toby Stuart , David Kiron , (No reviews yet) Write a Review Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? Find 424 listings related to Sirtris Pharmaceuticals Inc in Cambridge on YP.com. ", "Doubts Build On Glaxo's Antiaging Drugs", "Sirtuins: Antiaging Medicines or Marketing? [13][14], GSK/Sirtris terminated development of SRT501 in late 2010. Their latest funding was raised on Apr 19, 2006 from a Series C round. The Company discovers and develops proprietary, orally available, small molecule drugs. GlaxoSmithKline (NYSE: GSK) has announced that it has entered into a definitive acquisition pact with Sirtris Pharmaceuticals Inc. (NASDAQ: SIRT). SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, … Case Description of GSK's Acquisition of Sirtris: Independence or Integration? In most courses studied at Harvard Business schools, students are provided with a case study. Rare, Progressive Disorder Caused by Mutation in DNA of Mitochondria Has No Known Treatments CAMBRIDGE, MA, USA | August 9, 2007 | Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, today announced the initiation of a Phase 1b clinical trial … Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 -- Living in the United States has Advantages over living in my country America- A country of Immigrants. Dr. David Sinclair is co-founder of several biotechnology companies (Sirtris Pharmaceuticals, Genocea Biosciences, OvaScience, CohBar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others (most notably Shaklee). Sirtris has generated a lot of hype because it is developing anti-aging drugs, some of which are based on resveratrol, a chemical in red wine. See reviews, photos, directions, phone numbers and more for Sirtris Pharmaceuticals Inc locations in Cambridge, MA. Sirtris Pharmaceuticals: Living Healthier, Longer by Toby Stuart , David Kiron , (No reviews yet) Write a Review Sirtris Pharmaceuticals develops small molecule drugs for the treatment of aging and metabolic diseases. GSK is one of the largest pharmaceutical companies in the world, headquartered in London; it has significant products in both consumer and pharmaceutical areas. "Sirtris is delighted to welcome Mike, who brings to our team a wealth of experience in discovery research, particularly in the metabolic field," said Christoph Westphal, M.D., Ph.D., CEO of Sirtris Pharmaceuticals. Eric W Jacobson is Chief Medical Officer at Sirtris Pharmaceuticals Inc. See Eric W Jacobson's compensation, career history, education, & memberships. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … Sirtris Pharmaceuticals has raised a total of $82M in funding over 4 rounds. Xconomy Boston — [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five … 481 - 490 of 500 . San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. SIRTRIS PHARMACEUTICALS, INC. April 15, 2005. Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs … GlaxoSmithKline acquires Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer and merger of $22.50 per share, the firms state June 6. Explore. New Pathway for Developing Treatments for Diseases of Aging. We use cookies to provide you with a better experience. Sirtris Pharmaceuticals is funded by 10 investors. Pharmaceutical Preparations . Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body's natural defense against disease. David Sinclair Harvard Medical School Department of Pathology NRB, 9 th Floor 77 Avenue Louis Pasteur Boston, MA 02115. Conceived in 2004 by Harvard University biologist David Sinclair and serial entrepreneur Andrew Perlman,[1] and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel,[2] the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab. The buyout was another giant coup for Sirtris … Their focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). WhatsApp acquired by Facebook). Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … The field of sirtuins received high profile exposure last year when GlaxoSmithKline paid $720m to acquire Sirtris Pharmaceuticals, one of the few companies developing a clinical stage pipeline of products which interact with these enzymes which regulate multiple metabolic pathways. Should the company establish a proposed alliance with a pharmaceutical firm? Like all of them, I also came to the U.S, 6 months ago and I noticed that We can have access to Employment opportunities, which respect the worker’s rights. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that GSK says has the potential to generate multiple clinically and commercially important products. CLAIM THIS BUSINESS. Find 424 listings related to Sirtris Pharmaceuticals Inc in Cambridge on YP.com. Their focus to date has been on the development of SIRT1 activators for the treatment of Type 2 Diabetes Mellitus (T2DM). Discovery Reveals Critical Role of SIRT3 and SIRT4 in Cell Metabolism.